Hussein A Tawbi

Trials

Studies that name Hussein A Tawbi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 09:15 UTC. Open this list on ClinicalTrials.gov

• Ph1/Ph2
  NCT04789668 · Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

  M.D. Anderson Cancer Center · terminated · Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Hematopoietic and Lymphoid Cell Neoplasm · principal investigator
• Ph1
  NCT03816345 · Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  National Cancer Institute (NCI) · recruiting · Autoimmune Disease, Crohn Disease, Dermatomyositis · principal investigator
• Ph2
  NCT03175432 · Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

  M.D. Anderson Cancer Center · active not recruiting · BRAF V600 Wild Type, Clinical Stage IV Cutaneous Melanoma AJCC v8, Intracranial Melanoma · principal investigator
• Ph2
  NCT02910700 · Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

  M.D. Anderson Cancer Center · active not recruiting · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7 · principal investigator
• Ph1
  NCT01366144 · Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

  National Cancer Institute (NCI) · active not recruiting · Breast Carcinoma, Carcinoma of Unknown Primary, Endometrial Carcinoma · principal investigator
• N/A
  NCT01209299 · Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously Treated With Carboplatin and Paclitaxel With or Without Sorafenib Tosylate

  ECOG-ACRIN Cancer Research Group · completed · Melanoma (Skin) · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 09:15 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

• EARLY PHASE CLINICAL RESEARCH SUPPORT (Core 018)
  P30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · fiscal years 2015 to 2018 · $8,614 awarded in 2018
  Grant number is on one of their registry trials

NIH grants that fund their trials

These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.

• Texas EXperimental Cancer Therapeutics Network - TEX CTN
  UM1CA186688 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM, John Sarantopoulos, James C Yao · fiscal years 2014 to 2026
  Named on NCT03816345
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062490 · NCI · DANA-FARBER CANCER INST · PI DONALD W. KUFE · fiscal years 1994 to 2013
  Named on NCT01366144
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA062502 · NCI · CASE WESTERN RESERVE UNIVERSITY · PI AFSHIN DOWLATI · fiscal years 1994 to 2013
  Named on NCT01366144
• Phase I Molecular and Clincal Pharmacodynamic Trials
  U01CA062505 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI EDWARD M NEWMAN · fiscal years 1994 to 2013
  Named on NCT01366144
• Early Clinical Trials of New Anti-Cancer Agents with Phase 1 Emphasis
  U01CA069856 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI DAVID R SPRIGGS · fiscal years 1995 to 2013
  Named on NCT01366144
• Phase I Clinical Trials of New Anti-Cancer Targeted Therapies
  U01CA070095 · NCI · JOHNS HOPKINS UNIVERSITY · PI Michael A Carducci · fiscal years 1995 to 2013
  Named on NCT01366144
• Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis
  U01CA099168 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI EDWARD CHU · fiscal years 2003 to 2013
  Named on NCT01366144
• NCI ETCTN Pittsburgh Cancer Consortium (PCC)
  UM1CA186690 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI JOHN C. BYRD, Farshid Dayyani, Liza Cosca Villaruz · fiscal years 2014 to 2026
  Named on NCT01366144
• The Johns Hopkins Translational Science Team and Consortium for ETCTN Studies
  UM1CA186691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Jan Hendrik Beumer, Michael A Carducci, Ryan Gentzler, GLENN LIU, Wells A. Messersmith, Jimmy Ruiz · fiscal years 2014 to 2026
  Named on NCT01366144
• Extension of the Dana Farber Harvard Cancer Center Consortium for the ETCTN
  UM1CA186709 · NCI · DANA-FARBER CANCER INST · PI KEITH T FLAHERTY, DONALD W. KUFE, Geoffrey I. Shapiro · fiscal years 2014 to 2026
  Named on NCT01366144
• Wisconsin and New Jersey Alliance in Precision Experimental Therapeutics
  UM1CA186716 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI Salma Jabbour, GLENN LIU · fiscal years 2014 to 2019
  Named on NCT01366144
• Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN
  UM1CA186717 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI A. Dimitrios Colevas, Alexey V. Danilov, PRIMO N. LARA, HEINZ JOSEF LENZ · fiscal years 2014 to 2026
  Named on NCT01366144